Back to Search Start Over

BML-111 inhibits EMT, migration and metastasis of TAMs-stimulated triple-negative breast cancer cells via ILK pathway.

Authors :
Lin L
Luo X
Wang L
Xu F
He Y
Wang Q
Yuan C
Xu J
Yan L
Hao H
Source :
International immunopharmacology [Int Immunopharmacol] 2020 Aug; Vol. 85, pp. 106625. Date of Electronic Publication: 2020 May 30.
Publication Year :
2020

Abstract

Triple-negative breast cancer (TNBC) has a more aggressive phenotype and higher metastasis and recurrence rates than other breast cancer subtypes. The immune microenvironment and hypoxic microenvironment of breast cancer constitute the survival environment of cancer cells, which is an important environment to support cancer cells. LXA <subscript>4</subscript> and its analog, BML-111 is an important regulator of inflammatory cytokines, which provides a possible way for the treatment of inflammatory-related tumors. Here, in the in vitro experiment, we showed that BML-111 could inhibit the EMT and migration of TAMs-stimulated TNBC by down-regulating ILK as well as p-Akt and p-GSK3β. And it could prevent the formation of breast cancer cell clusters. In the in vivo experiment, BML-111 could inhibit the metastasis of 4T1 breast cancer cells. We also demonstrated that BML-111 could affect macrophages in tumor microenvironment to prevent metastasis. These results showed that BML-111 could be a possible candidate for breast cancer therapy by targeting ILK and TAMs.<br />Competing Interests: Declaration of Competing Interest The authors declare that there is no conflict of interests regarding the publication of this paper.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1878-1705
Volume :
85
Database :
MEDLINE
Journal :
International immunopharmacology
Publication Type :
Academic Journal
Accession number :
32485356
Full Text :
https://doi.org/10.1016/j.intimp.2020.106625